

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	Not applicable	<i>In vitro</i> and mouse studies suggest that the hypoxia-activated cancer therapeutic TH-302 could help treat MM. TH-302 induced cell cycle arrest in MM cells under hypoxic conditions but not under normal oxygen concentrations. In a mouse model of MM, TH-302 yielded more apoptosis, lower microvessel density and less angiogenesis than did vehicle. Next steps could include testing the compound in more animal models of MM. Threshold Pharmaceuticals Inc.'s TH-302 is in Phase I/II trials to treat solid tumors.	Threshold owns all patent and licensing rights to TH-302	Hu, J. <i>et al. Blood</i> ; published online June 7, 2010; doi:10.1182/blood-2010-02-269126 Contact: Karin Vanderkerken, Vrije Universiteit Brussel, Brussels, Belgium e-mail: karin.vanderkerken@vub.ac.be
		SciBX 3(26); doi:10.1038/scibx.2010.790 Published online July 1, 2010		